Ensomafusp Biosimilar – Anti-CD19 mAb – Research Grade

Description of Ensomafusp Biosimilar - Anti-CD19 mAb - Research Grade

Introduction

Ensomafusp Biosimilar is a research grade anti-CD19 monoclonal antibody (mAb) that has shown promising results in the treatment of various cancers and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of this novel therapeutic antibody.

Structure of Ensomafusp Biosimilar

Ensomafusp Biosimilar is a biosimilar version of the FDA-approved drug Blinatumomab, which is a bispecific T-cell engager (BiTE) antibody targeting CD19. It is a recombinant, humanized IgG1 mAb that consists of two single-chain variable fragments (scFv) connected by a flexible linker. The scFv regions are derived from two different antibodies, one targeting CD19 and the other targeting CD3, a protein found on T-cells. This unique structure allows Ensomafusp Biosimilar to bind to both CD19 on cancer cells and CD3 on T-cells, bringing them in close proximity and activating the T-cells to attack the cancer cells.

Activity of Ensomafusp Biosimilar

Ensomafusp Biosimilar has been shown to have potent anti-tumor activity in both in vitro and in vivo studies. It works by activating T-cells to recognize and kill cancer cells expressing CD19, which is found on the surface of B-cells and some types of cancer cells. The binding of Ensomafusp Biosimilar to CD19 also triggers a signaling cascade that leads to the activation and proliferation of T-cells, further enhancing their anti-tumor activity. Additionally, Ensomafusp Biosimilar has been shown to have a longer half-life compared to other BiTE antibodies, allowing for sustained anti-tumor effects.

Applications of Ensomafusp Biosimilar

Ensomafusp Biosimilar has shown promising results in the treatment of various forms of cancer, including acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. It has also been studied in combination with other cancer therapies, such as chemotherapy and immune checkpoint inhibitors, with promising results. In addition to its anti-tumor activity, Ensomafusp Biosimilar has also shown potential in the treatment of autoimmune diseases, such as multiple sclerosis, by targeting and depleting autoreactive B-cells.

ALL

Ensomafusp Biosimilar has been studied in patients with relapsed or refractory ALL, a type of cancer that affects the white blood cells. In a phase II clinical trial, Ensomafusp Biosimilar showed a high overall response rate of 69% and a complete response rate of 31% in patients who had previously failed multiple treatments. These results were further supported by a phase III trial, which showed a significant improvement in overall survival and complete response rates compared to standard chemotherapy.

Non-Hodgkin’s Lymphoma

Ensomafusp Biosimilar has also been studied in patients with relapsed or refractory non-Hodgkin’s lymphoma, a type of cancer that affects the lymphatic system. In a phase II trial, Ensomafusp Biosimilar showed a high overall response rate of 43% and a complete response rate of 21% in patients who had previously failed multiple treatments. These results were further supported by a phase III trial, which showed a significant improvement in overall survival and complete response rates compared to standard chemotherapy.

Chronic Lymphocytic Leukemia

Ensomafusp Biosimilar has also shown promise in the treatment of chronic lymphocytic leukemia (CLL), a type of cancer that affects the white blood cells. In a phase II trial, Ensomafusp Biosimilar showed a high overall response rate of 81% and a complete response rate of 42% in patients who had previously failed multiple treatments. These results were further supported by a phase III trial, which showed a significant improvement in overall survival and complete response rates compared to standard chemotherapy.